Methylprednisolone for the treatment of Immune-mediates Diseases flares. Relationship between doses, effectiveness and safety. A pilot study.
Background: Methylprednisolone (MTP) pulses have proved effectiveness for the treatment of severe manifestations of immune-mediated diseases (ID). However, the the relationship between doses, effectiveness and safety is not well established.Objective: To know MTP indications, doses, therapeutic resp...
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | Artículo revista |
| Lenguaje: | Español |
| Publicado: |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología
2017
|
| Materias: | |
| Acceso en línea: | https://revistas.unc.edu.ar/index.php/med/article/view/16460 |
| Aporte de: |
| id |
I10-R327-article-16460 |
|---|---|
| record_format |
ojs |
| institution |
Universidad Nacional de Córdoba |
| institution_str |
I-10 |
| repository_str |
R-327 |
| container_title_str |
Revista de la Facultad de Ciencias Médicas de Córdoba |
| language |
Español |
| format |
Artículo revista |
| topic |
methylprednisolone effectiveness drug-related side effects and adverse reactions dose-response relationship drug metilprednisolona efectividad seguridad dosis |
| spellingShingle |
methylprednisolone effectiveness drug-related side effects and adverse reactions dose-response relationship drug metilprednisolona efectividad seguridad dosis Danza Galdo, Álvaro Methylprednisolone for the treatment of Immune-mediates Diseases flares. Relationship between doses, effectiveness and safety. A pilot study. |
| topic_facet |
methylprednisolone effectiveness drug-related side effects and adverse reactions dose-response relationship drug metilprednisolona efectividad seguridad dosis |
| author |
Danza Galdo, Álvaro |
| author_facet |
Danza Galdo, Álvaro |
| author_sort |
Danza Galdo, Álvaro |
| title |
Methylprednisolone for the treatment of Immune-mediates Diseases flares. Relationship between doses, effectiveness and safety. A pilot study. |
| title_short |
Methylprednisolone for the treatment of Immune-mediates Diseases flares. Relationship between doses, effectiveness and safety. A pilot study. |
| title_full |
Methylprednisolone for the treatment of Immune-mediates Diseases flares. Relationship between doses, effectiveness and safety. A pilot study. |
| title_fullStr |
Methylprednisolone for the treatment of Immune-mediates Diseases flares. Relationship between doses, effectiveness and safety. A pilot study. |
| title_full_unstemmed |
Methylprednisolone for the treatment of Immune-mediates Diseases flares. Relationship between doses, effectiveness and safety. A pilot study. |
| title_sort |
methylprednisolone for the treatment of immune-mediates diseases flares. relationship between doses, effectiveness and safety. a pilot study. |
| description |
Background: Methylprednisolone (MTP) pulses have proved effectiveness for the treatment of severe manifestations of immune-mediated diseases (ID). However, the the relationship between doses, effectiveness and safety is not well established.Objective: To know MTP indications, doses, therapeutic response and safety in the clinical setting.Methodology: A retrospective review of records was performed in Hospital Pasteur of Uruguay, from patients who had received MTP during a ID flare. Variables studied: age, sex, MTP cumulative doses, duration of treatment, therapeutic response and adverse effects.Results: Thirty six cases were identified, 26 were female. The mean age was 41,5 (SD 15,5) years. The mean dose of MTP in cases of complete response was 3,6 (SD 2) grams, the mean dose in cases of partial response was 4 (SD 1,5) grams, and in cases of no response was 2,8 (SD 1,2) grams (p> 0,05). The mean dose in patients with adverse effects was 4,4 (SD 1,8) grams, and in cases without adverse effects was 3,2 (SD 1,6) grams (p<0,05).Conclusions: Our series does not confirm a relationship between higher doses and clinical response. However, an association between higher doses of MTP and adverse effects was observed. These finding should be thoroughly investigated. |
| publisher |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología |
| publishDate |
2017 |
| url |
https://revistas.unc.edu.ar/index.php/med/article/view/16460 |
| work_keys_str_mv |
AT danzagaldoalvaro methylprednisoloneforthetreatmentofimmunemediatesdiseasesflaresrelationshipbetweendoseseffectivenessandsafetyapilotstudy AT danzagaldoalvaro metilprednisolonaenbrotesdeenfermedadesinmunomediadasrelacionentredosisefectividadyseguridadestudiopiloto |
| first_indexed |
2024-09-03T20:58:28Z |
| last_indexed |
2024-09-03T20:58:28Z |
| _version_ |
1809209998505410560 |
| spelling |
I10-R327-article-164602024-08-27T18:20:28Z Methylprednisolone for the treatment of Immune-mediates Diseases flares. Relationship between doses, effectiveness and safety. A pilot study. Metilprednisolona en brotes de enfermedades inmunomediadas: relación entre dosis, efectividad y seguridad. Estudio Piloto Danza Galdo, Álvaro methylprednisolone effectiveness drug-related side effects and adverse reactions dose-response relationship drug metilprednisolona efectividad seguridad dosis Background: Methylprednisolone (MTP) pulses have proved effectiveness for the treatment of severe manifestations of immune-mediated diseases (ID). However, the the relationship between doses, effectiveness and safety is not well established.Objective: To know MTP indications, doses, therapeutic response and safety in the clinical setting.Methodology: A retrospective review of records was performed in Hospital Pasteur of Uruguay, from patients who had received MTP during a ID flare. Variables studied: age, sex, MTP cumulative doses, duration of treatment, therapeutic response and adverse effects.Results: Thirty six cases were identified, 26 were female. The mean age was 41,5 (SD 15,5) years. The mean dose of MTP in cases of complete response was 3,6 (SD 2) grams, the mean dose in cases of partial response was 4 (SD 1,5) grams, and in cases of no response was 2,8 (SD 1,2) grams (p> 0,05). The mean dose in patients with adverse effects was 4,4 (SD 1,8) grams, and in cases without adverse effects was 3,2 (SD 1,6) grams (p<0,05).Conclusions: Our series does not confirm a relationship between higher doses and clinical response. However, an association between higher doses of MTP and adverse effects was observed. These finding should be thoroughly investigated. INTRODUCCIÓN: Metilprednisolona (MTP) es una molécula con probada efectividad antiinflamatoria e inmunosupresora para la terapia en pulsos de brotes de enfermedades inmunomediadas (EI). Sin embargo, no se conoce con certeza la mejor relación entre dosis, efectividad y efectos adversos.OBJETIVO: Conocer los usos de MTP, dosis, respuesta terapéutica y efectos adversos. MATERIAL Y MÉTODOS: Se realizó un estudio retrospectivo de pacientes que recibieron MTP en el Hospital Pasteur de Uruguay. Se incluyeron pacientes que recibieron MTP en pulsos por una enfermedad inmunomediada. Se analizaron las siguientes variables: edad, sexo, dosis acumulada de MTP, duración del tratamiento con MTP, respuesta terapéutica, efectos adversos. RESULTADOS: Se identificaron 36 casos, 27 de sexo femenino. La media de edad fue 41,5 (DE: 15,5) años. La media de dosis en los casos de respuesta completa fue 3,6 (DE: 2) gramos; la media de dosis en los casos de respuesta parcial fue 4 (DE: 1,5) gramos; la media de dosis de no respuesta fue 2,8 (DE 1,2) gramos (p> 0,05). La media de dosis en los pacientes que presentaron efectos adversos fue 4,4 (DE: 1,8) gramos y la media de dosis de los que no presentaron efectos adversos fue 3,2 (DE: 1,6) gramos (p<0,05).DISCUSIÓN: Nuestra serie sugiere que no existe una clara relación entre dosis mayores y mejores respuestas terapéuticas. Sin embargo, existe una mayor tendencia a presentar efectos adversos con dosis más elevadas. Estos hallazgos refuerzan la necesidad de racionalizar las dosis de MTP y continuar estudiando este tema en con mayor número de pacientes. Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2017-12-08 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion application/pdf application/vnd.openxmlformats-officedocument.wordprocessingml.document application/vnd.openxmlformats-officedocument.wordprocessingml.document https://revistas.unc.edu.ar/index.php/med/article/view/16460 10.31053/1853.0605.v74.n4.16460 Revista de la Facultad de Ciencias Médicas de Córdoba.; Vol. 74 No. 4 (2017); 355-360 Revista de la Facultad de Ciencias Médicas de Córdoba; Vol. 74 Núm. 4 (2017); 355-360 Revista da Faculdade de Ciências Médicas de Córdoba; v. 74 n. 4 (2017); 355-360 1853-0605 0014-6722 10.31053/1853.0605.v74.n4 spa https://revistas.unc.edu.ar/index.php/med/article/view/16460/19547 https://revistas.unc.edu.ar/index.php/med/article/view/16460/26337 https://revistas.unc.edu.ar/index.php/med/article/view/16460/26338 Derechos de autor 2017 Universidad Nacional de Córdoba https://creativecommons.org/licenses/by-nc/4.0 |